Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features

Clinical Cancer Research

Volumn 15, Issue 22, 2009, Pages 6800-6809

  Sredni, Simone T ^a   Gadd, Samantha ^a   Huang, Chiang Ching ^a   Breslow, Norman ^b   Grundy, Paul ^c   Green, Daniel M ^d   Dome, Jeffrey S ^e   Shamberger, Robert C ^f   Beckwith, J Bruce ^g   Perlman, Elizabeth J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WT1 PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CELL DIFFERENTIATION; CHILD; CHROMOSOME 11P; CHROMOSOME 16Q; CHROMOSOME 1P; CLINICAL FEATURE; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NEPHROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; TISSUE MICROARRAY;

CHILD, PRESCHOOL; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LOSS OF HETEROZYGOSITY; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; QUALITY CONTROL; RECURRENCE; RISK; WILMS TUMOR; WT1 PROTEINS;

EID: 72549092942     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0312     Document Type: Article

References (32)

1. Green DM, Jaffe N. The role of chemotherapy in the treatment of Wilms tumor. Cancer 1979;44:52-57 (Pubitemid 9234909)
2. Green DM, Breslow NE, Beckwith JB, Takashima J, Kelalis P, D'Angio GJ. Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms tumors: a report from the National Wilms Tumor Study. J Clin Oncol 1993;11:91-95
3. Green DM, Breslow NE, Beckwith JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2001;19:3719-3724
4. Huang CC, Gadd S, Breslow NB, et al. Predicting relapse in favorable histology Wilms tumor using gene expression analysis. A report from the Renal Tumor Committee of the Children's Oncology Group. Clin Cancer Res 2009;15:1770-1778
5. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorablehistology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2005;23:7312-7321
6. Huang CC, Cutcliffe C, Coffin C, Sorensen PH, Beckwith JB, Perlman EJ. Classification of malignant pediatric renal tumors by gene expression. Pediatr Blood Cancer 2006;46:728-738 (Pubitemid 43726420)
7. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-264
8. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-14868
9. Brunskill EW, Aronow BJ, Georgas K, et al. Atlas of gene expression in the developing kidney at microanatomic resolution. Dev Cell 2008;15:781-791
10. Li CM, Guo M, Borczuk A, et al. Gene expression in Wilms tumor mimics the earliest committed stage in the metanephric mesenchymal- epithelial transition. Am J Pathol 2002;160:2181-2190
11. Li W, Kessler P, Yeger H, et al. A gene expression signature for relapse of primary Wilms tumors. Cancer Res 2005;65:2592-2601
12. Beckwith JB, Zuppan CE, Browning NG, Moksness J, Breslow NE. Histological analysis of aggressiveness and responsiveness in Wilms tumor. Med Pediatr Oncol 1996;27:422-428
13. Li CM, Kim CE, Margolin AA, et al. CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant Wilms tumors. Am J Pathol 2004;165:1943-1953
14. Folgueira MA, Carraro DM, Brentani H, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005;11:7434-7443 (Pubitemid 41507704)
15. Weirich A, Leuschner I, Harms D, et al. Clinical impact of histologic subtypes in localized nonanaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol 2001;12:311-319 (Pubitemid 32288685)
16. Schwab K, Patterson LT, Aronow BJ, Luckas R, Liang HC, Potter SS. A catalogue of gene expression in the developing kidney. Kidney Int 2003; 64:1588-1604
17. Schmidt-Ott KM, Masckauchan TN, Chen X, et al. β-catenin/TCF/Lef controls a differentiation-associated transcriptional programin renal epithelial progenitors. Development 2007;134:3177-3190
18. Self M, Lagutin OV, Bowling B, et al. Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J 2006;25:5214-5228 (Pubitemid 44658538)
19. Matsell DG, Delhanty PJ, Stepaniuk O, Goodyear C, Han VK. Expression of insulin-like growth factor and binding protein genes during nephrogenesis. Kidney Int 1994;46:1031-1042 (Pubitemid 24319941)
20. Zhou R, Diehl D, Hoeflich A, Lahm H, Wolf E. IGF-binding protein-4: biochemical characteristics and functional consequences. J Endocrinol 2003;178:177-193 (Pubitemid 37063060)
21. Christians JK, Hoeflich A, Keightley PD. PAPPA2, an enzyme that cleaves an insulin-like growth-factor-binding protein, is a candidate gene for a quantitative trait locus affecting body size in mice. Genetics 2006;173:1547-1553
22. Van Dyck F, Declercq J, Braem CV, Van de Ven WJ. PLAG1, the prototype of the PLAG gene family: versatility in tumour development [review]. Int J Oncol 2007;30:765-774
23. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-686 (Pubitemid 46510744)
24. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008;114:23-37.
25. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008;451:583-586
26. Izumi H, Inoue J, Yokoi S, et al. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum Mol Genet 2005;14:997-1007. (Pubitemid 40575875)
27. Huff V. Wilms tumor genetics. Am J Med Genet 1998;79:260-267
28. Schumacher V, Schneider S, Figge A, et al. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology. Proc Natl Acad Sci U S A 1997;94:3972-3977
29. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms tumor. Pediatr Pathol 1990;10:1-36. (Pubitemid 20130951)
30. Englert C, Hou X, Maheswaran S, et al. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J 1995;14:4662-4675
31. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001;273:141-161 (Pubitemid 32786908)
32. D'Angio GJ, Rosenberg H, Sharples K, Kelalis P, Breslow N, Green DM. Position paper: imaging methods for primary renal tumors of childhood: costs versus benefits. Med Pediatr Oncol 1993;21:205-212 (Pubitemid 23084332)